Table 4.
Characteristics of Prescribed VTE Prophylaxis Methods
| Frequency | % of Total | |
|---|---|---|
| Indication of VTE prophylaxis | ||
| In all patients (N=240) | 29 | 12.1 |
| Subgroups | ||
| In low risk VTE patients (N=35) | 1 | 2.9 |
| In moderate risk VTE patients (N=80) | 3 | 3.8 |
| In high risk VTE patients (N=125) | 25 | 20 |
| Major PAS for cancer (N=86) | 26 | 30.2 |
| Choice of VTE prophylaxis methods | ||
| Pharmacological methods | 29 | 12.1 |
| Mechanical methods | 0 | 0 |
| Characteristics of anticoagulant use | ||
| Enoxaparin as anticoagulant agent | 29 | 100 |
| Dose of enoxaparin | ||
| 40 mg q24h | 28 | 96.6 |
| 40 mg q12h | 1 | 3.4 |
| Time of initiation postoperative | ||
| 12 to 24h postoperative | 13 | 44.8 |
| More than 24h postoperative | 15 | 51.7 |
| More than 48h postoperative | 1 | 3.5 |
| Length of enoxaparin prophylaxis use (days) | ||
| Mean ± SD | 5.5 ± 1.7 | |
| < 5 days | 8 | 27.6 |
| 5–6 days | 14 | 48.3 |
| 7–10 days | 7 | 24.1 |
| Length of prophylaxis in VTE risk subgroup (days) | ||
| Moderate risk of VTE (N=3) | 5.7 ± 1.5 | |
| High risk of VTE (N=25) | 5.6 ± 1.8 | |
| Major tumor resection surgery (N=26) | 5.5 ±1.8 | |
| Post discharge prophylaxis for major PAS for cancer (N=26) | 0 | 0 |